Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: an observational cross-sectional study

Summary Sixty patients diagnosed with generalized anxiety disorder and treated with either paroxetine, sertraline, or citalopram for at least 12 months were enrolled in this study, and the bone mineral density (BMD) of the patients was compared with that of 40 healthy volunteers. Selective serotonin...

Full description

Saved in:

Bibliographic Details
Published in:	Osteoporosis international Vol. 26; no. 1; pp. 273 - 279
Main Authors:	Ak, E., Bulut, S. D., Bulut, S., Akdağ, H. A., Öter, G. B., Kaya, H., Kaya, O. B., Şengül, C. B., Kısa, C.
Format:	Journal Article
Language:	English
Published:	London Springer London 01-01-2015 Springer Nature B.V
Subjects:	Aged Anxiety Anxiety Disorders - drug therapy Bone density Bone Density - drug effects Cross-Sectional Studies Drug therapy Endocrinology Female Femur - physiopathology Humans Lumbar Vertebrae - physiopathology Medicine Medicine & Public Health Middle Aged Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - chemically induced Osteoporosis, Postmenopausal - physiopathology Psychiatric Status Rating Scales Rheumatology Serotonin Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - pharmacology Serotonin Uptake Inhibitors - therapeutic use BMD Osteoporosis SSRI GAD
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Sixty patients diagnosed with generalized anxiety disorder and treated with either paroxetine, sertraline, or citalopram for at least 12 months were enrolled in this study, and the bone mineral density (BMD) of the patients was compared with that of 40 healthy volunteers. Selective serotonin reuptake inhibitor (SSRI) therapy in generalized anxiety disorder was found to be related with decreased BMD values. Introduction The objectives of this study were to evaluate the effect of SSRI therapy on BMD in postmenopausal women diagnosed with generalized anxiety disorder (GAD) and to identify the effects of the duration of disease and treatment on risk factors for osteoporosis. Methods Sixty patients diagnosed with GAD and treated with paroxetine, sertraline, or citalopram from the SSRI group for at least 12 months were enrolled. Social demographic features, the Hamilton Anxiety Scale (HAS) results, and the Hamilton Depression Scale (HDS) scores of all the patients were assessed. The BMD of the patients was measured by dual-energy X-ray absorptiometry (DXA) at the femoral and lumbar regions. The patients were divided into three groups which are the paroxetine, sertraline, and citalopram groups. The BMD of the patients was compared with that of 40 healthy volunteers. Results The L2–L4, total lumbar vertebrae, femoral intertrochanteric, total femoral Z-scores, and femoral Ward’s region T-scores of the treatment group were lower than the median T- and Z-scores of the control group ( p < 0.05). Of the treatment groups, the femoral neck, trochanteric and intertrochanteric T- and Z-scores, total femoral T- and Z-scores, and femoral Ward’s T- and Z-scores of the sertraline group were significantly lower than the BMD values measured at the identical regions in the paroxetine and citalopram groups ( p < 0.05).There was a significant negative correlation between the duration of treatment and the BMD values. Conclusion SSRI therapy in GAD was found to be related with decreased BMD values. Further randomized controlled studies are warranted to determine whether SSRI use is a risk factor for osteoporosis; such studies should investigate these factors by performing BMD assessments before treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0937-941X 1433-2965
DOI:	10.1007/s00198-014-2859-2